BioInvent International AB held a key opinion leader event on May 27, 2026, to discuss ovarian cancer treatments and TNFR2-targeted therapies.
The virtual event featured company executives and external expert Dmitriy Zamarin. Martin Welschof, president and CEO, opened the session and outlined the agenda covering the treatment landscape and company progress.
Riportato dall'IA Immagine generata dall'IA Verificato
Researchers led by Umeå University pathologist Maréne Landström report that a fully human antibody aimed at an oncogenic form of TGF‑β receptor I (TβRI) signaling suppressed tumor growth and metastasis in preclinical models of advanced prostate cancer. The study was published in Signal Transduction and Targeted Therapy.
Yasuo Urata, president of Oncolys BioPharma, reflected on the long development process after the company received approval for a viral therapy targeting esophageal cancer.
Riportato dall'IA
Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.
A protein called NFIL3 has been identified as a key factor in reducing the long-term performance of CAR T cells used in cancer treatment. Researchers showed that disabling this protein allows the engineered cells to remain active longer and fight tumors more effectively in laboratory models.
Riportato dall'IA
Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.